Global Myomectomy Market Insights Forecasts to 2033.

• The Global Myomectomy Market Size was Valued at USD 2.9 Billion in 2023.
• The Market Size is Growing at a CAGR of 8.90% from 2023 to 2033.
• The Worldwide Myomectomy Market Size is Expected to Reach USD 6.8 Billion by 2033.
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Myomectomy Market Size is Anticipated to Exceed USD 6.8 Billion by 2033, Growing at a CAGR of 8.90% from 2023 to 2033.

Market Overview

A myomectomy is a surgical treatment used to remove fibroids, which are growths that occur in or on a woman's uterus but are not malignant. The number, size, and location of the fibroids will determine the sort of myomectomies that can be done. The main drivers anticipated to drive the market are the rising number of less invasive treatments, the rising number of individuals with uterine fibroids and related disorders, and the rising usage of technologically sophisticated technologies for safe and successful myomectomy procedures. Individuals with uterine fibroids have a significant opportunity for industry expansion. The best treatment for fibroids that also protects the uterus is a myomectomy. A myomectomy can be done in a variety of ways, depending on the location and size of the fibroids. The launch of cutting-edge products because of the rise in myomectomy surgeries performed for uterine fibroids is anticipated to promote market expansion. Technological developments like the development of robotically aided myomectomy operations and laparoscopic surgery have demonstrated incision-less surgery for the treatment of fibroids with negligible to no adverse effects. The government's and nonprofit groups' enhanced initiatives for fibroids treatment are also anticipated to fuel market expansion throughout the projected period.

Report Coverage

This research report categorizes the global myomectomy market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global myomectomy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global myomectomy market.                 

Driving Factors

A significant majority of women, especially those in their reproductive years, suffer from uterine fibroids, which are frequently benign tumors. For instance, the Illinois Department of Public Health estimates that uterine fibroids might affect 77% of women who are of childbearing age. Therefore, the need for effective treatment options to control the symptoms that come from uterine fibroids is increasing as more women receive diagnoses for the condition. In addition, the use of minimally invasive methods for myomectomy is growing, such as robotic-assisted surgery and laparoscopy. The need for myomectomy treatments is fueled by the increasing prevalence of uterine fibroids, which is driving the market's rise. The myomectomy market is expanding significantly due to the revolutionary changes in myomectomy techniques brought about by technological improvements. Instead of making a huge abdominal incision, physicians can now perform intricate surgeries using tiny incisions for new treatments like robotic and laparoscopic myomectomy. Individuals benefit from a shorter recovery period following surgery, less blood loss and scarring, and a decreased chance of problems and infections.

Restraining Factors

A myomectomy might affect a person's ability to conceive even if the procedure's main objective is to remove uterine fibroids and preserve fertility. The ability to conceive might be affected by uterine scarring or alterations resulting from the surgical procedure. This is particularly true if multiple or large fibroids are removed. The future desire to have parents is impacted in women who worry about possible issues with their fertility after a myomectomy. The surgical surgery might result in uterine scarring or changes, which could potentially impact the ability to conceive. This is especially the case if several or big fibroids are removed. Women who are concerned about potential problems with their fertility following a myomectomy have an impact on their desire to become parents in the future.

Market Segmentation

The global myomectomy market share is classified into type, product, and end-use. 

• The abdominal myomectomy segment is expected to hold the largest share of the global myomectomy market during the forecast period.   

Based on the type, the global myomectomy market is divided into abdominal myomectomy, hysteroscopic myomectomy, and laparoscopic myomectomy. Among these, the abdominal myomectomy segment is expected to hold the largest share of the global myomectomy market during the forecast period. This is attributed to a rising number of individuals with uterine fibroids, which raises the need for myomectomy operations as a treatment. Furthermore, this procedure is recognized as the gold standard of care for uterine preservation, fibroid removal, and preserving the ability of individuals to become fertile. For uterine fibroids, it is the only long-term treatment available. Therefore, it is expected that growth in myomectomy treatments will propel market expansion.

• The laparoscopic sealer segment is expected to hold the largest share of the global myomectomy market during the forecast period.

Based on the product, the global myomectomy market is divided into laparoscopic power morcellators, harmonic scalpels, and laparoscopic sealers. Among these, the laparoscopic sealer segment is expected to hold the largest share of the global myomectomy market during the forecast period. This is attributed to the minimally invasive nature of myomectomy procedures, which results in smaller incisions, less blood loss, shorter hospital stays, and quicker recovery times, pushing more and more individuals to choose for them. Additionally, by permitting precise tissue sealing and cutting, laparoscopic sealers increase surgical precision and reduce the risk of complications.

• The hospitals & clinics segment is expected to hold the highest market share of the global myomectomy market during the forecast period.   

Based on the end-use, the global myomectomy market is divided into hospitals & clinics and ambulatory surgical centers. Among these, the hospitals & clinics segment is expected to hold the largest share of the global myomectomy market during the forecast period. This is attributed to the presence of skilled surgeons and gynecologists guarantees better patient outcomes and fosters patient and provider confidence. Furthermore, a larger patient base can obtain myomectomy services due to hospitals' and clinics' widespread accessibility and function as referral centers. Therefore, it is expected that the elements will drive market trends.

Regional Segment Analysis of the Global Myomectomy Market

• North America (U.S., Canada, Mexico) 
• Europe (Global, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global myomectomy market over the predicted timeframe.

North America is anticipated to hold the largest share of the global myomectomy market over the predicted timeframe. The existence of significant players and the availability of surgical procedure reimbursement. Furthermore, a sedentary lifestyle and an aging population have raised the incidence of fibroids. In addition, rising government healthcare spending and an increase in hospitalization due to rising cases of uterine fibroids are additional drivers promoting growth in the area.

Asia Pacific is expected to grow the fastest during the forecast period. Growing awareness of managing diseases has led to increased attention to women's health issues. This is leading an increasing number of women to choose early-stage surgery. Medical equipment manufacturers from both abroad and domestically are aggressively looking for commercial opportunities in the nation. To meet the enormous unmet demand, they are growing their manufacturing facilities and launching cutting-edge laparoscopic devices.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global myomectomy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Medtronic
• Stryker Corporation
• CONMED Corporation
• INSIGHTEC
• Cooper Surgical Inc
• Hologic, Inc
• Intuitive Surgical
• Karl Storz, B
• Braun Melsungen AG
• Minerva Surgical Inc
• Ethicon, Inc
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In August 2021, Hologic Inc., a worldwide pioneer in women's health, announced that Anthem Blue Cross Blue Shield, the second-biggest insurance plan in the United States, has revised its medical policy to include coverage for women with uterine fibroids for radiofrequency ablation (LAP-RFA), which includes the Acessa procedure (CPT Code 58674).

• In October 2021, Gynesonics, a women's healthcare organization dedicated to creating minimally invasive treatments for uterine fibroids that are symptomatic, announced that Dr. John Thoppil is the first medical professional in Texas to provide the Sonata treatment as an office-based procedure to women with uterine fibroids at his River Place OB/GYN facility in Austin, Texas.

Market Segment

This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the global myomectomy market based on the below-mentioned segments:

Global Myomectomy Market, By Type

• Abdominal Myomectomy
• Hysteroscopic Myomectomy
• Laparoscopic Myomectomy

Global Myomectomy Market, By Product

• Laparoscopic Power Morcellators
• Harmonic Scalpel
• Laparoscopic Sealer

Global Myomectomy Market, By End-Use

• Hospitals & Clinics
• Ambulatory Surgical Centers

Global Myomectomy Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa